$THC

KERREY J ROBERT sold $64K of THC

KERREY J ROBERT sold 361 shares of TENET HEALTHCARE CORP (THC) at $177.52 on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information but does not include new company fundamentals (no earnings, guidance, deal, or regulatory action). Traders may only adjust positioning tactically around insider-flow narratives.

02

Market read

A director’s open-market sale at a specific price is a low-signal, sentiment-only datapoint for THC.

03

What to watch

The article doesn’t state whether the sale was part of a broader planned program or for tax/estate needs; absence of a 10b5-1 plan can increase speculation but still lacks fundamental context.

Relevance 6/10Novelty 6/10Timing: Filed 2026-05-29 after sale dated 2026-05-28

Background

This is an SEC Form 4 insider transaction for Tenet Healthcare (THC), reporting an open-market sale by a director.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director KERREY J ROBERT sold 361 shares in an open-market transaction at $177.52 on 2026-05-28.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than earnings- or deal-driven.

Evidence & confidence

The filing is an ownership-change disclosure (insider sale) with no stated operational or financial trigger; size is relatively small versus typical market cap noise.

Market effects

Minimal; single-company insider sale without guidance/earnings changes is unlikely to reset sector expectations.

None indicated.

None indicated.

Counterpoint

Insider sales are often routine (tax/portfolio rebalancing) and may not reflect negative fundamentals, especially without a 10b5-1 plan disclosure.

Key entities

  • TENET HEALTHCARE CORP

    Subject of the Form 4 insider sale disclosure.

  • KERREY J ROBERT

    Director who sold 361 shares on 2026-05-28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

$THCMedAI 8/10

Tenet Healthcare at Wells Fargo conference: high-acuity push deepens

Tenet Healthcare (THC) presented at the Wells Fargo Healthcare Conference, outlining a strategy focused on high-acuity care, capital spending, and cost control. The company raised full-year guidance, citing volume growth and cost discipline. Shares are near their 52-week high at $268.82, up over 30% year-to-date. Tenet expects continued pressure in some payer channels and near-term earnings drag from Conifer's transition. Management plans to invest in complex procedures and maintain capital spen